About Us > Scientific Advisory Board
Prof. Robert Huber, FRS
Robert is one of the leading authorities in the world on structural biology focussing on X-ray crystallography of complex proteins. He was awarded the Nobel Prize for Chemistry in 1988 for the determination of the three-dimensional structure of a photosynthetic reaction centre. He is the former Director of the Max Planck Institute of Biochemistry in Munich and headed the department of Structural Research. Prof. Huber has been involved with setting up and advising a number of biotechnology companies.
Dr Timothy Wells
Timothy is Chief Scientific Officer at Medicines for Malaria Venture. He was previously Senior Executive Vice-President of R&D at Serono. There, his responsibilities included drug innovation and development, taking programmes from target validation through pre-clinical development to completion of Phase I studies. His research group in Geneva in the mid 90's focused on cytokine immunology and identified several new chemokines and their receptors, and pioneered the application of these molecules in a wide range of diseases, from allergy through to HIV. He has over 170 publications and several patent applications.
Prof. Antal Rot
Antal is Professor of Immunology at Birmingham University, UK. He was previously Group Head at the Novartis Institute of Biomedical Research in Vienna, and is a key figure in the field of chemokine biology and the role of chemokines in inflammatory diseases. He has published many seminal papers, including articles on the interaction between chemokines and cell-surface glycan structures. He initially trained as a medical doctor and Pathologist, and carried out post-doctoral research at the National Institutes of Health in the US.
Prof. Timothy Williams
Timothy is Professor of Applied Pharmacology at the National Heart & Lung Institute at Imperial College London. He is also Head of the Leukocyte Biology Section. Timothy is a leading expert on chemokine biology and an inventor on a number of patents related to the chemokine Eotaxin. He has been a Consultant and served on the Scientific Advisory Boards of many companies including LeukoSite Inc., Pfizer, Merck, GSK, and Cambridge Antibody Technology.
Prof. John Gallagher
John is Professor of Medical Oncology at the Patterson Institute of Cancer Research at the University of Manchester. He is one of the leading authorities in the world of Heparan Sulphate and the role of GAGs in human disease. He has been a Consultant and Scientific Advisory Board member for a number of companies including Oxford Glycosciences and Endotis.
Dr. Marco Sardina, MD
Marco is Medical Director of Strategic Development at Zambon Company an international pharmaceutical company headquartered in Milan that focuses on the commercialisation of anti-inflammatory, respiratory, and anti-infective products. Prior to his current role, Marco worked at NicOx SA, Italfarmaco, Schering-Plough, Ciba-Geigy and Knoll in various positions. He is author on 80 scientific publications and a regular speaker at international conferences.
Prof. Barret Rollins, MD
Barret is Chief Scientific Officer of the Dana-Faber Cancer Institute and Linde Family Professor of Medicine, Harvard Medical School. After graduating from Amherst College, he received his MD in 1979 and PhD in 1980 from Case Western Reserve University. He completed his internship and residency in internal medicine at Beth Israel Hospital, Boston. He then served a clinical fellowship in medical oncology at DFCI and a postdoctoral research fellowship with Dr. Charles Stiles. Since joining DFCI in 1989, Barret has worked in the area of white blood cell trafficking and the interactions between inflammation and cancer. Barret is a world leader in chemokine biology.